Survodutide

What is Survodutide? Survodutide is an investigational dual agonist targeting both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). Developed by Boehringer Ingelheim and Zealand Pharma, it has been studied in preclinical and early clinical models for its potential effects on metabolic regulation, including energy balance and body weight modulation. Research has focused on its relevance to obesity and metabolic dysfunction-associated steatohepatitis (MASH), with ongoing studies exploring its mechanisms of action and therapeutic potential. For Research Use Only. Not intended for human consumption, medical, diagnostic, or therapeutic purposes.